{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rheumatoid+Arthritis%2C+NOS&page=7", "query": { "condition": "Rheumatoid Arthritis, NOS", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1118, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rheumatoid+Arthritis%2C+NOS&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rheumatoid+Arthritis%2C+NOS&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T05:25:59.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00808210", "title": "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-03-05", "completion_date": "2012-11-14", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808210" }, { "nct_id": "NCT06312020", "title": "A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjogren's Syndrome" ], "interventions": [ { "name": "HZN-1116", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 209, "start_date": "2024-05-09", "completion_date": "2026-04-28", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 16, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Napa, California + 13 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Napa", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312020" }, { "nct_id": "NCT05152615", "title": "A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Short Chain Fatty Acids (SCFA) Dietary Supplement", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-11-17", "completion_date": "2024-03-15", "has_results": false, "last_update_posted_date": "2024-06-24", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05152615" }, { "nct_id": "NCT04115020", "title": "Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis", "Arthritis, Rheumatoid", "Arthritis, Psoriatic" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-01", "completion_date": "2020-01-07", "has_results": false, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115020" }, { "nct_id": "NCT04634253", "title": "A Study of LY3462817 in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "LY3462817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2021-01-04", "completion_date": "2022-06-29", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 7, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Palm Desert, California + 4 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634253" }, { "nct_id": "NCT02886728", "title": "Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "Placebo to match MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1252, "start_date": "2016-08-08", "completion_date": "2019-05-08", "has_results": true, "last_update_posted_date": "2021-06-01", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 45, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02886728" }, { "nct_id": "NCT00420927", "title": "Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1032, "start_date": "2006-12", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-04-18", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420927" }, { "nct_id": "NCT06339957", "title": "Rheumatology Diet Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diet Habit", "Rheumatologic Disease", "Autoimmune Diseases", "Rheumatoid Arthritis", "Psoriatic Arthritis", "Ankylosing Spondylitis", "Dermatomyositis/polymyositis", "Sjogren's Syndrome", "Systemic Lupus Erythematous", "Scleroderma", "Fibromyalgia" ], "interventions": [], "intervention_types": [], "sponsor": "University of Central Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 500, "start_date": "2024-03-01", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06339957" }, { "nct_id": "NCT04512573", "title": "Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)" ], "interventions": [], "intervention_types": [], "sponsor": "CorEvitas", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 232, "start_date": "2020-05-21", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04512573" }, { "nct_id": "NCT00264537", "title": "A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo injections", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" }, { "name": "Methotrexate capsules", "type": "DRUG" }, { "name": "Golimumab 50 mg injections", "type": "BIOLOGICAL" }, { "name": "Golimumab 100 mg injections", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2005-12", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-10-07T05:25:59.184Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Upland", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00264537" } ] }